Study of efficacy and safety of dapagliflozin with CKD patients without diabetes and proteinuria

INTERVENTION: Group A: Dapagliflozin 10mg per day will be administered orally for 12 months. GroupB: Current treatment will be continued for 12 months. CONDITION: Chronic kidney disease G3A1, A2 ; renal insufficiency D007676 PRIMARY OUTCOME: The rate of change in eGFR between 1 month and 12month after the beginning of study SECONDARY OUTCOME: 1)Composite renal outcome, which is the first occurence of any of the following; the onset of end‐stage kidney disease(defined as maintenance dialysis, kidney transplantation, or an estimated GFR of <15mL/min/1.73, a decline of at least 50% in the 2)estimated GFR or death from renal causes; 2)Rate of newly onset of proteinuria; 3)Changes of blood pressure INCLUSION CRITERIA: 1)Female or male aged between 20 and 84 2)eGFR 30 or more AND less than 60 mL/min/1.73 3)Urinary protein to creatinine ratio less than 0.50g/gCr OR negative in dip stick method 4)Patients who have given written consent to participate in the study from the individual (or a surrogate)